2-Chlor-3-<2-hydroxy-anilino>-naphthochinon-(1.4) | 1092-07-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-Chlor-3-<2-hydroxy-anilino>-naphthochinon-(1.4)
• 英文别名: 2-Chloro-3-[(2-hydroxyphenyl)amino]naphthalene-1,4-dione；2-chloro-3-(2-hydroxyanilino)naphthalene-1,4-dione
• CAS: 1092-07-5
• 化学式: C₁₆H₁₀ClNO₃
• 分子量: 299.713
• InChiKey: VCFUZBMYVIQWFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Chlor-3-<2-hydroxy-anilino>-naphthochinon-(1.4) 、 苯磺酰氯 在 三乙胺 作用下， 以85%的产率得到12-benzenesulphonylbenzo[b]-12H-phenoxazine-6,11-dione
  参考文献：
  名称：

  用于合成多核杂环体系的氯烯胺醌的新活化方法

  摘要：

  醌类化合物 1a-f 和 7 中氯烯胺酮的氯原子通过与苯磺酰氯反应活化形成萘醌部分与线性或有角杂环系统稠合，如咔唑 2a-c 、吩嗪 3a 、b 和 5a-c 、吩恶嗪 3c吩噻嗪3d、喹喔啉吩嗪6a、喹喔啉吩恶嗪6b、喹喔啉吩噻嗪6c、恶二嗪8、噻二嗪9和吡唑10。讨论了后一种衍生物的机理。给出了所有新产品的光谱数据。此外，还筛选了一些报道化合物的抗微生物活性。

  DOI：

  10.1080/10426500307929
• 作为产物：
  描述：

  2,3-二氯-1,4-萘醌 、 2-氨基苯酚 生成 2-Chlor-3-<2-hydroxy-anilino>-naphthochinon-(1.4)
  参考文献：
  名称：

  KOPELTSIV, YU. A.;KLEP, V. Z.;GRUSHETSKAYA, I. I., BECTH. LVOV. POLITEXN. IN-TA,(1988) N 221, 49-50

  摘要：

  DOI：

文献信息

• COMPOSITIONS AND METHODS FOR TREATING ALZHEIMERS DISEASE
  申请人：Puglielli Luigi

  公开号：US20120329789A1

  公开（公告）日：2012-12-27

  Pharmaceutical compositions for treating Alzheimer's disease are disclosed. The pharmaceutical compositions include a compound having the general formula: and a pharmaceutically acceptable carrier. Methods for treating Alzheimer's disease, inhibiting ATase I and/or ATase 2, reducing the activity of BACE1, reducing the level of amyloid β-peptide (Aβ), and/or reducing the level of APP intracellular domain peptide (AICD) by administering such compositions are also disclosed.
• Compositions and Methods for Treating Alzheimers Disease
  申请人：Wisconsin Alumni Research Foundation

  公开号：US20150182477A1

  公开（公告）日：2015-07-02

  Pharmaceutical compositions for treating Alzheimer's disease are disclosed. The pharmaceutical compositions include a compound having the general formula: and a pharmaceutically acceptable carrier. Methods for treating Alzheimer's disease, inhibiting ATase I and/or ATase 2, reducing the activity of BACE1, reducing the level of amyloid β-peptide (Aβ), and/or reducing the level of APP intracellular domain peptide (AICD) by administering such compositions are also disclosed.
• US8980884B2
  申请人：——

  公开号：US8980884B2

  公开（公告）日：2015-03-17
• US9522124B2
  申请人：——

  公开号：US9522124B2

  公开（公告）日：2016-12-20
• [EN] COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2012166862A1

  公开（公告）日：2012-12-06

  Pharmaceutical compositions for treating Alzheimer's disease are disclosed. The pharmaceutical compositions include a compound having the general formula: and a pharmaceutically acceptable carrier. Methods for treating Alzheimer's disease, inhibiting ATase I and/or ATase 2, reducing the activity of BACEl, reducing the level of amyloid β-peptide (Αβ), and/or reducing the level of APP intracellular domain peptide (AICD) by administering such compositions are also disclosed.